- Home
- RWAY vs ITOS Comparison
RWAY vs ITOS Comparison
Compare RWAY & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWAY
- ITOS
- Stock Information
- Founded
- RWAY 2015
- ITOS 2011
- Country
- RWAY United States
- ITOS United States
- Employees
- RWAY N/A
- ITOS N/A
- Industry
- RWAY
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RWAY
- ITOS Health Care
- Exchange
- RWAY Nasdaq
- ITOS Nasdaq
- Market Cap
- RWAY 410.4M
- ITOS 450.9M
- IPO Year
- RWAY 2021
- ITOS 2020
- Fundamental
- Price
- RWAY $10.70
- ITOS N/A
- Analyst Decision
- RWAY Buy
- ITOS Hold
- Analyst Count
- RWAY 6
- ITOS 6
- Target Price
- RWAY $11.00
- ITOS $10.40
- AVG Volume (30 Days)
- RWAY 252.5K
- ITOS 1.6M
- Earning Date
- RWAY 08-07-2025
- ITOS 08-06-2025
- Dividend Yield
- RWAY 13.08%
- ITOS N/A
- EPS Growth
- RWAY 153.06
- ITOS N/A
- EPS
- RWAY 1.91
- ITOS N/A
- Revenue
- RWAY $140,975,000.00
- ITOS N/A
- Revenue This Year
- RWAY N/A
- ITOS N/A
- Revenue Next Year
- RWAY N/A
- ITOS N/A
- P/E Ratio
- RWAY $5.59
- ITOS N/A
- Revenue Growth
- RWAY N/A
- ITOS 177.89
- 52 Week Low
- RWAY $8.35
- ITOS $4.80
- 52 Week High
- RWAY $11.73
- ITOS $17.63
- Technical
- Relative Strength Index (RSI)
- RWAY 46.62
- ITOS 1.63
- Support Level
- RWAY $10.60
- ITOS $10.10
- Resistance Level
- RWAY $10.92
- ITOS $10.17
- Average True Range (ATR)
- RWAY 0.14
- ITOS 0.03
- MACD
- RWAY -0.00
- ITOS -1.20
- Stochastic Oscillator
- RWAY 49.43
- ITOS 0.00
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.